U.S. Biopharmacy Company AbbVie to Buy Botox Maker Allergan for Around $63 Billion
U.S. biopharmacy company AbbVie said on Tuesday it had agreed to buy Allergan, the maker of Botox, in a stock and cash operation worth about $63 billion.
The offer represents a 45 percent premium over Monday's share price of Irish-registered Allergan, whose management recommended the operation to shareholders.
The deal, which AbbVie CEO Richard Gonzalez called "transformational", is to close early in 2020.
The combined companies will generate around $48 billion in revenues this year, AbbVie said.
"Combining Allergan's diversified on-market product portfolio with AbbVie's growth platform and deep expertise in R&D, commercial strength and international footprint will create a leading biopharmaceutical company," it said.
The new company would boost earnings per share by 10 percent in its first year, the U.S. company predicted.
AbbVie's main areas of expertise are immunology, oncology, virology and neuroscience.
Allergan, best known for the hugely popular cosmetic treatment Botox, specialises in the areas of medical aesthetics, eye care, central nervous system and gastroenterology.
Its portfolio also includes Humira, a best-selling treatment for rheumatoid arthritis.